<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Valacyclovir: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Valacyclovir: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Valacyclovir: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10034" href="/d/html/10034.html" rel="external">see "Valacyclovir: Drug information"</a> and <a class="drug drug_patient" data-topicid="11133" href="/d/html/11133.html" rel="external">see "Valacyclovir: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F56870012"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Valacyclovir-Containing Products Safety Review</span>
<span class="collapsible-date">June 2022</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">After a safety review, Health Canada has concluded that there may be a link between the use of valacyclovir-containing products and the potential risk of drug reaction with eosinophilia and systemic symptoms (DRESS). This safety review was triggered by updates made by the European Medicines Agency to the product safety information for valacyclovir-containing products to include the risk of DRESS. Health Canada will work with manufacturers to update the Canadian product safety information for valacyclovir-containing products to include the risk of DRESS.</p>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fhpr-rps.hres.ca%2Freg-content%2Fsummary-safety-review-detail.php%3Flang%3Den%26linkID%3DSSR00284%2520&amp;token=hASon4tO4BxBucgIolxGFdI3avh90qRB6iETwfuz6CxdsI0rcrT2GrPlFxKnE%2FfYCpMyEDna6jkB0U4dshFkFMktI2kYLLdZDQPEALzXtx8k%2BRkOtI3wiTmum1gGVviuAbnrFfRpnne4AsrNyZpn%2FA%3D%3D&amp;TOPIC_ID=13001" target="_blank">https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&amp;linkID=SSR00284</a>.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F232799"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Valtrex</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868550"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Valacyclovir;</li>
<li>APO-Valacyclovir;</li>
<li>Auro-Valacyclovir;</li>
<li>BIO-Valacyclovir [DSC];</li>
<li>DOM-Valacyclovir [DSC];</li>
<li>JAMP Valacyclovir;</li>
<li>JAMP-Valacyclovir;</li>
<li>Mar-Valacyclovir [DSC];</li>
<li>MYLAN-Valacyclovir;</li>
<li>PMS-Valacyclovir;</li>
<li>Priva-Valacyclovir [DSC];</li>
<li>PRO-Valacyclovir;</li>
<li>RIVA-Valacyclovir;</li>
<li>SANDOZ Valacyclovir;</li>
<li>TEVA-Valacyclovir;</li>
<li>Valtrex</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1041673"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiviral Agent, Oral</span></li></ul></div>
<div class="block dop drugH1Div" id="F232813"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="96306a66-94e4-4129-a3ec-a291c736a69c">Herpes simplex virus, orolabial infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus (HSV), orolabial infection: Note: </b>Initiate at earliest symptom onset.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients without HIV</i>: Treatment:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing: Limited data available: Infants ≥3 months, Children, and Adolescents: Oral: 20 mg/kg/dose every 12 hours; maximum dose: 1,000 mg/dose. In immunocompetent patients, treat for 5 to 7 days; immunocompromised patients may require 10 to 14 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelsons.1','lexi-content-ref-20014952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelsons.1','lexi-content-ref-20014952'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing: Children ≥12 years and Adolescents: Oral: 2,000 mg every 12 hours for 1 day (2 doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with HIV</i>: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Treatment: Adolescents: Oral: 1,000 mg every 12 hours for 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Suppressive therapy (eg, for severe or frequent recurrences): Adolescents: Oral: 500 mg every 12 hours; reassess continued need annually (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e2b01a83-a4d2-4d7a-80a1-c067cbf6fbe0">Herpes simplex virus, genital infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus (HSV), genital infection:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>First episode; treatment: </i>Children and Adolescents: Oral: 20 mg/kg/dose every 12 hours; maximum dose: 1,000 mg/dose. Treat for 7 to 10 days; some patients may need a longer duration if lesions are incompletely healed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelsons.1','lexi-content-ref-34292926','lexi-content-ref-HHS.2','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelsons.1','lexi-content-ref-34292926','lexi-content-ref-HHS.2','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Recurrent episode; treatment:</i>
<b>Note:</b> Most effective if started during prodrome or within 1 day lesion appearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Oral: 20 mg/kg/dose every 12 hours; maximum dose: 1,000 mg/dose. Treat for 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelsons.1','lexi-content-ref-34292926','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelsons.1','lexi-content-ref-34292926','lexi-content-ref-HHS.2'])">Ref</a></span>). Alternatively, adolescents who are <b>not</b> HIV infected may receive 500 mg every 12 hours for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Suppressive therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Patients without HIV: Adolescents: Oral: 20 mg/kg/dose once daily; maximum dose: 500 mg/dose. In adolescents with frequent recurrences (ie, ≥10 per year), doses of 1,000 mg/day may be more effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelsons.1','lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelsons.1','lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients with HIV: Adolescents: Oral: 500 mg every 12 hours; reassess continued need annually (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-HHS.2','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-HHS.2','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e1613b7d-9150-49e0-8df2-96c7201803f2">Herpes simplex virus, prophylaxis in immunocompromised patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus (HSV), prophylaxis in immunocompromised patients (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hematopoietic cell transplant (HCT) recipients, seropositive</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: <b>Note: </b>To prevent early reactivation, begin at initiation of conditioning and continue until engraftment or resolution of mucositis; to prevent late reactivation, continue throughout the first year following HCT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-17515400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-17515400'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;40 kg: Oral: 250 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: Oral: 500 mg once or twice daily; use twice-daily dosing in highly suppressed patients (eg, high-dose steroids, T cell depletion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Solid organ transplant recipients, seropositive:</i>
<b>Note</b>: Administer for ≥1 month after transplant and during treatment of rejection episodes.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Oral: 20 mg/kg/dose twice daily; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859647'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e7bc6fa-f3f3-4346-982a-01ee6e4ad790">Herpes zoster, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes zoster (shingles; caused by varicella zoster virus [VZV]), treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In immunocompromised patients with extensive lesions, visceral involvement, disseminated disease, or who are &lt;2 years of age, initial parenteral treatment is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: Oral: 20 mg/kg/dose every 8 hours; maximum dose: 1,000 mg/dose. Treat for at least 7 to 10 days and until lesions have crusted over; lesions resolving more slowly may require longer treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31162727','lexi-content-ref-Nelsons.1','lexi-content-ref-HHS.2','lexi-content-ref-HHS.3','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31162727','lexi-content-ref-Nelsons.1','lexi-content-ref-HHS.2','lexi-content-ref-HHS.3','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e2080c20-66a0-4ae8-9e50-c42d708a5051">Varicella zoster virus, prophylaxis in HCT recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella zoster virus (VZV) (chickenpox), prophylaxis in HCT recipients (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: <b>Note: </b>Begin within 48 hours if possible; continue for 22 days postexposure.</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;40 kg: Oral: 500 mg every 8 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: Oral: 1,000 mg every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention of VZV reactivation in seropositive patients</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;40 kg: Oral: 250 or 500 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-17515400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-17515400'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: Oral: 500 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-17515400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-17515400'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9e17c390-a777-415e-a881-5526b86711fd">Varicella zoster virus, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella zoster virus (VZV) (chickenpox), treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Treatment not routinely recommended in otherwise healthy younger children; consider treatment in individuals at high risk for moderate to severe disease (eg, unvaccinated adolescents, patients with chronic cutaneous or pulmonary conditions, patients on long-term salicylate therapy or receiving corticosteroids). Parenteral acyclovir is generally recommended for immunocompromised patients; oral therapy may be considered in select cases when outcome is expected to be good or as oral step-down therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31162727','lexi-content-ref-HHS.3','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31162727','lexi-content-ref-HHS.3','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents &lt;18 years: Limited data available in patients &lt;2 years of age: Oral: 20 mg/kg/dose every 8 hours for 5 days; maximum dose: 1,000 mg/dose; initiate as soon as possible and within 24 hours of rash onset. In immunocompromised patients, treat for 7 to 14 days, dependent upon clinical response; patients with HIV may need 4 to 6 weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelsons.1','lexi-content-ref-HHS.3','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelsons.1','lexi-content-ref-HHS.3','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="07ac5600-81b7-48ee-827b-32cd612b3698">Varicella zoster virus, acute retinal necrosis; step-down therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella zoster virus, acute retinal necrosis; step-down therapy: </b>Limited data available: HIV-infected: Adolescents: 1,000 mg every 8 hours for ≥14 weeks (following initial treatment with IV acyclovir) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51193224"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> There are no pediatric-specific dose adjustments provided in the manufacturer's labeling; however, the following adjustments are recommended for adults receiving similar initial dosages.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes labialis:</b> Adolescents: Based on usual dose of 2,000 mg every 12 hours for 2 doses.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 49 mL/minute: 1,000 mg every 12 hours for 2 doses.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to 29 mL/minute: 500 mg every 12 hours for 2 doses.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: 500 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Genital herpes:</b> Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Initial episode: Based on usual dose of 1,000 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 29 mL/minute: 1,000 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: 500 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Recurrent episode: Based on usual dose of 500 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≤29 mL/minute: 500 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Suppressive therapy: CrCl ≤29 mL/minute:</p>
<p style="text-indent:-2em;margin-left:6em;">For usual dose of 1,000 mg every 24 hours, decrease dose to 500 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">For usual dose of 500 mg every 24 hours, decrease dose to 500 mg every 48 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">HIV-infected patients: 500 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Dialyzable (~33% removed during 4-hour session); administer dose postdialysis.</p></div>
<div class="block dohp drugH1Div" id="F51193225"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥2 years and Adolescents: No dosage adjustment necessary.</p></div>
<div class="block doa drugH1Div" id="F232803"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10034" href="/d/html/10034.html" rel="external">see "Valacyclovir: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01d3e8c6-1ec1-4614-aae2-225baffa4c00">Bell palsy, new onset</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bell palsy, new onset (adjunctive therapy) (off-label use):</b>
<b>Oral:</b> 1 g three times daily for 7 days in combination with corticosteroids; begin within 3 days of symptom onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24189771','lexi-content-ref-12656408','lexi-content-ref-18849193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24189771','lexi-content-ref-12656408','lexi-content-ref-18849193'])">Ref</a></span>). <b>Note:</b> Antiviral therapy alone is <b>not</b> recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23136264','lexi-content-ref-24189771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23136264','lexi-content-ref-24189771'])">Ref</a></span>); some experts only recommend addition of an antiviral to steroid therapy in patients with severe Bell palsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24934895','lexi-content-ref-18778190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24934895','lexi-content-ref-18778190'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6c9f3c6-bafb-4ad0-824e-df01eb873650">Cytomegalovirus, prevention in allogeneic hematopoietic cell transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, prevention in allogeneic hematopoietic cell transplant recipients (alternative agent) (off-label use): </b>
<b>Oral:</b> 2 g three to four times daily, beginning at engraftment and continued to day 100 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>) <b>or</b> 2 g three times daily, started after initial therapy with IV ganciclovir from day −8 to day −2 prior to transplant, and continued until engraftment or longer in patients on glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21937692','lexi-content-ref-Wingard.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21937692','lexi-content-ref-Wingard.1'])">Ref</a></span>). <b>Note:</b> Combine with screening for CMV reactivation (due to weak activity) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d4bb7a35-a81a-4ee3-aa35-32b821836e34">Herpes simplex virus, meningitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus, meningitis (off-label use): Oral:</b> 1 g three times daily, to complete a 10- to 14-day course following clinical improvement with IV acyclovir. <b>Note: </b>Not recommended for herpes simplex virus encephalitis, which requires treatment with IV acyclovir (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-18582201']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-18582201'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc927598-72d2-4e9c-90f1-41398e5be5e9">Herpes simplex virus, mucocutaneous infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus, mucocutaneous infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Genital:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Patients who are immunocompetent:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment, initial episode</i>: <b>Oral</b>: 1 g twice daily for 7 to 10 days; extend duration if lesion has not healed completely after 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment, recurrent episode</i>: <b>Oral:</b> 500 mg twice daily for 3 days <b>or</b> 1 g once daily for 5 days. <b>Note:</b> Treatment is most effective when initiated during the prodrome or within 1 day of lesion onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Suppressive therapy (eg, for severe and/or frequent recurrences)</i>: <b>Oral:</b> 500 mg or 1 g once daily. <b>Note:</b> Reassess need periodically (eg, annually). The 500 mg daily dose may be less effective in patients who experience very frequent (≥10) recurrences per year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients who are immunocompromised (including patients with HIV):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment, initial or recurrent episode</i>: <b>Oral:</b> 1 g twice daily for 5 to 10 days (7 to 10 days for initial episode in patients with HIV); extend treatment duration if lesions have not healed completely after 10 days. <b>Note:</b> Treat severe disease initially with IV acyclovir; may switch to valacyclovir when lesions begin to regress and continue for &gt;10 days total and until lesions have resolved completely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Suppressive therapy (eg, for severe and/or frequent recurrences)</i>: <b>Oral:</b> 500 mg twice daily. <b>Note: </b>Reassess need periodically (eg, annually) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Pregnant patients:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment, initial episode (alternative agent)</i>: <b>Oral:</b> 1 g twice daily for 7 to 10 days; extend duration if lesion has not healed completely after 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332414','lexi-content-ref-Riley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332414','lexi-content-ref-Riley.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment, recurrent episode (symptomatic) (alternative agent)</i>: <b>Oral:</b> 500 mg twice daily for 3 days <b>or</b> 1 g once daily for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332414'])">Ref</a></span>). <b>Note:</b> Some experts reserve treatment of recurrent episodes for patients with severe and/or frequent symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Riley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Riley.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Suppressive therapy, for patients with a genital herpes simplex virus lesion anytime during pregnancy (alternative agent)</i>: <b>Oral:</b> 500 mg twice daily, beginning at 36 weeks' gestation and continued until delivery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332414','lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332414','lexi-content-ref-34292926'])">Ref</a></span>); some experts recommend discontinuing suppressive therapy at the onset of labor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Riley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Riley.1'])">Ref</a></span>). <b>Note:</b> For patients with a primary infection during the third trimester, may consider suppressive therapy earlier than 36 weeks’ gestation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332414'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Orolabial:</b></i>
<b>Note:</b> Initiate therapy at earliest symptom.</p>
<p style="text-indent:-2em;margin-left:6em;">Patients who are immunocompetent:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment, initial infection (eg, gingivostomatitis): </i>
<b>Oral:</b> 1 g twice daily for 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12626280','lexi-content-ref-Wald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12626280','lexi-content-ref-Wald.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment, recurrent infection (eg, cold sores)</i>: <b>Oral:</b> 2 g twice daily for 1 day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Suppressive therapy (eg, for severe and/or frequent recurrences)</i>: <b>Oral:</b> 500 mg or 1 g once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12661753','lexi-content-ref-17668537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12661753','lexi-content-ref-17668537'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients who are immunocompromised (including patients with HIV):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment, initial or recurrent infection</i>: <b>Oral:</b> 1 g twice daily for 5 to 10 days and until complete lesion resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Suppressive therapy (eg, for severe and/or frequent recurrences)</i>: <b>Oral:</b> 500 mg twice daily. <b>Note:</b> Reassess need periodically (eg, annually) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="28cbc4d6-be78-4a44-8380-de87dfb2fee6">Herpes simplex virus, prevention in patients who are immunocompromised</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus, prevention in patients who are immunocompromised (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Seropositive HCT recipients (allogeneic or autologous) or seropositive patients undergoing leukemia induction chemotherapy: <b>Oral:</b> 500 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-12621507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-12621507'])">Ref</a></span>). <b>Note:</b> Initiate with the chemotherapeutic or conditioning regimen and continue until recovery of WBC count and resolution of mucositis; duration may be extended in patients with frequent recurrences or graft-vs-host disease (GVHD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-30179565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-30179565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Solid organ transplant recipients (patients who are HSV-seropositive who do <b>not</b> require CMV prophylaxis): <b>Oral:</b> 500 mg twice daily for ≥1 month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859647'])">Ref</a></span>); some experts recommend continuing for 3 to 6 months after transplantation and during periods of lymphodepletion associated with treatment of rejection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fishman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fishman.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e7bc6fa-f3f3-4346-982a-01ee6e4ad790">Herpes zoster, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes zoster (shingles), treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Initiate at earliest sign or symptom. Antiviral treatment is most effective ≤72 hours after rash onset but may be initiated &gt;72 hours in certain situations (eg, new lesions continue to appear); for patients who are immunocompromised, initiate treatment even if &gt;72 hours after symptom onset unless all lesions have crusted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10375341','lexi-content-ref-HHS.2','lexi-content-ref-29746903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10375341','lexi-content-ref-HHS.2','lexi-content-ref-29746903'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute localized dermatomal lesion(s):</i>
<b>Oral:</b> 1 g three times daily for 7 to 10 days; for slowly improving lesions, may extend therapy until resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31162727','lexi-content-ref-10375341','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31162727','lexi-content-ref-10375341','lexi-content-ref-HHS.2'])">Ref</a></span>). For select patients who are immunocompromised at high risk of dissemination (eg, recent transplant, graft-versus-host disease), some experts suggest regimens used for disseminated zoster (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17143845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17143845'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Disseminated zoster (extensive cutaneous lesions or visceral involvement):</i>
<b>Oral:</b> Initial therapy with acyclovir IV may be switched to valacyclovir 1 g three times daily to complete a 10- to 14-day course when formation of new lesions has ceased and signs/symptoms of visceral infection are improving (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31162727','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31162727','lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e4ae1e71-37b4-405a-801f-a90b24f24b65">Herpes zoster ophthalmicus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes zoster ophthalmicus (off-label use):</b>
<b>Oral:</b> 1 g three times daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10919899']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10919899'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c495c07a-7120-4d57-9730-7e3a51be10d9">Varicella, uncomplicated, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella (chickenpox), uncomplicated, treatment:</b>
<b>Oral:</b> 1 g three times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31162727','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31162727','lexi-content-ref-HHS.2'])">Ref</a></span>). <b>Note:</b> Ideally initiate therapy within 24 hours of symptom onset, but may start later if patient still has active skin lesions; continue treatment for at least 5 to 7 days and until all lesions have crusted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>). In patients who are immunocompromised (eg, solid organ transplant recipients), some experts recommend a minimum duration of 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31162727']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31162727'])">Ref</a></span>). Patients who are immunocompromised generally require IV acyclovir; however, for patients with uncomplicated or mild disease (&lt;50 lesions), some experts treat with valacyclovir (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Albrecht.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Albrecht.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27347e7a-98ba-4a26-8be9-6bc5faf6fab4">Varicella zoster virus, acute retinal necrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella zoster virus, acute retinal necrosis (off-label use): Oral: </b>1 g three times daily following initial treatment with IV acyclovir (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17123607','lexi-content-ref-12055471','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17123607','lexi-content-ref-12055471','lexi-content-ref-HHS.2'])">Ref</a></span>); in patients with HIV, duration is ≥14 weeks and intravitreal ganciclovir may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3bb78c6-48fd-48c8-8b56-8e34a0dfab1d">Varicella zoster virus, prevention in patients who are immunocompromised</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella zoster virus, prevention in patients who are immunocompromised (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">HCT recipients (allogeneic and autologous):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Postexposure prophylaxis:</i>
<b>Oral:</b> 1 g three times daily; initiate within 96 hours (preferably within 48 hours) of exposure and continue until 22 days after exposure. <b>Note:</b> Indicated following exposure <b>if varicella-zoster immune globulin is unavailable</b> in seronegative HCT recipients who are &lt;24 months after HCT <b>or</b> &gt;24 months after HCT and on immunosuppressive therapy or have chronic GVHD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prevention of VZV reactivation in seropositive patients:</i>
<b>Oral:</b> 500 mg twice daily for 1 year following transplantation; may extend duration in patients requiring ongoing immunosuppression (some experts continue prophylaxis in these patients until 6 months after discontinuation of all systemic immunosuppression) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Solid organ transplant recipients (patients who are VZV-seropositive who do <b>not</b> require CMV prophylaxis): <b>Oral:</b> 500 mg twice daily for 3 to 6 months after transplantation and during periods of lymphodepletion associated with treatment of rejection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31162727','lexi-content-ref-Fishman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31162727','lexi-content-ref-Fishman.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991799"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>The following adjustments are based on usual doses up to 4 g/day. There are no specific dosage adjustment recommendations for patients receiving &gt;4 g/day (eg, cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients [off-label use]); consultation with nephrology and/or transplant specialists is recommended in patients with altered kidney function.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<table border="1" frame="border" rules="all">
<caption>
<b>Valacyclovir Dose Adjustments for Kidney Impairment<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>CrCl </b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>If usual recommended dose is 500 mg every 24 hours </b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>If usual recommended dose is 1 g every 24 hours or 500 mg every 12 hours </b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>If usual recommended dose is 1 g every 12 hours</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b> If usual recommended dose is 1 g every 8 hours </b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>If usual recommended dose is 2 g every 12 hours for 2 doses</b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="6">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Manufacturer’s labeling.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">≥50 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30 to &lt;50 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 12 hours for 2 doses</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10 to &lt;30 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 48 hours</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 12 hours for 2 doses</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;10 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 48 hours</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg as a single dose</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post-trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Use the indication-specific maximum allowable dose along with therapeutic drug monitoring of acyclovir to support valacyclovir dosing when available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (33% removed during 4-hour session).</p>
<p style="text-indent:-2em;margin-left:4em;">500 mg every 24 hours; give after dialysis when given on dialysis day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26167456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26167456'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> 500 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12021536']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12021536'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">Usual recommended dose: 500 mg to 1 g every 12 to 24 hours along with therapeutic drug monitoring of acyclovir to support valacyclovir dosing when available; for less severe infections, a maximum daily dose of 1.5 g/<b>day</b> is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">Usual recommended dose: 500 mg to 1 g every 12 to 24 hours along with therapeutic drug monitoring of acyclovir to support valacyclovir dosing when available; for less severe infections, a maximum daily dose of 1.5 g/<b>day</b> is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989072"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block arsc drugH1Div" id="F54964540"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">As a prodrug of acyclovir, valacyclovir may also cause<b> acute kidney injury</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35509998','lexi-content-ref-19187258','lexi-content-ref-16172845','lexi-content-ref-36399320','lexi-content-ref-34032768','lexi-content-ref-35764333','lexi-content-ref-30222448','lexi-content-ref-34182607','lexi-content-ref-18180255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35509998','lexi-content-ref-19187258','lexi-content-ref-16172845','lexi-content-ref-36399320','lexi-content-ref-34032768','lexi-content-ref-35764333','lexi-content-ref-30222448','lexi-content-ref-34182607','lexi-content-ref-18180255'])">Ref</a></span>). Like acyclovir, this may result most often from obstructive nephropathy but may also be due to interstitial nephritis or renal tubular necrosis. Kidney injury is reversible in most cases after dosage reduction or discontinuation; however, some cases may not return to baseline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19187258','lexi-content-ref-16172845','lexi-content-ref-30741619','lexi-content-ref-30083888','lexi-content-ref-18180255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19187258','lexi-content-ref-16172845','lexi-content-ref-30741619','lexi-content-ref-30083888','lexi-content-ref-18180255'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; not clearly established, multiple proposed mechanisms. Usually attributed to the formation of acyclovir crystals, which result in intrarenal obstruction and nephropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10225250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10225250'])">Ref</a></span>). May also be due to glomerular hyperfiltration; injury may occur because kidneys have little reserve, resulting in an intolerance to nephrotoxic insult or increased filtrate delivery to the renal tubules (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32404442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32404442'])">Ref</a></span>). Other proposed mechanisms include an immune reaction that may contribute to interstitial nephritis and a major metabolite of acyclovir (9-carboxymethoxymethylguanine [CMMG]) that may be directly cytotoxic to cells of the renal tubule (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22005269']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22005269'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; reported cases range from 1 to 9 days of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35509998','lexi-content-ref-19187258','lexi-content-ref-16172845','lexi-content-ref-36399320','lexi-content-ref-34032768','lexi-content-ref-35764333','lexi-content-ref-34182607','lexi-content-ref-18180255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35509998','lexi-content-ref-19187258','lexi-content-ref-16172845','lexi-content-ref-36399320','lexi-content-ref-34032768','lexi-content-ref-35764333','lexi-content-ref-34182607','lexi-content-ref-18180255'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Less established than with acyclovir, but may include:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19187258','lexi-content-ref-Shaik.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19187258','lexi-content-ref-Shaik.2019'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30222448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30222448'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Preexisting kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30222448','lexi-content-ref-18180255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30222448','lexi-content-ref-18180255'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30222448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30222448'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30222448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30222448'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent use of nephrotoxic agents (eg, nonsteroidal anti-inflammatory drugs, vancomycin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30741619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30741619'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">As a prodrug of acyclovir, valacyclovir may also cause neurotoxicity. Acyclovir-induced neurotoxicity most commonly includes reported symptoms such as <b>agitation</b>, <b>confusion</b>, <b>dysarthria</b>, <b>hallucination</b>, and <b>impaired consciousness </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35509998','lexi-content-ref-16172845','lexi-content-ref-16540518','lexi-content-ref-36399320','lexi-content-ref-35764333','lexi-content-ref-33777579','lexi-content-ref-10847274','lexi-content-ref-14692893','lexi-content-ref-35832570','lexi-content-ref-29877263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35509998','lexi-content-ref-16172845','lexi-content-ref-16540518','lexi-content-ref-36399320','lexi-content-ref-35764333','lexi-content-ref-33777579','lexi-content-ref-10847274','lexi-content-ref-14692893','lexi-content-ref-35832570','lexi-content-ref-29877263'])">Ref</a></span>). Other reported symptoms include aphasia, <b>ataxia</b>, <b>myoclonus</b>, <b>tremor</b>, and <b>seizure</b> (including status epilepticus) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16540518','lexi-content-ref-24368610','lexi-content-ref-28765478','lexi-content-ref-14692893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16540518','lexi-content-ref-24368610','lexi-content-ref-28765478','lexi-content-ref-14692893'])">Ref</a></span>). Most cases of neurotoxicity are reversible after discontinuation with or without hemodialysis; however, some cases may not be fully reversible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31794437','lexi-content-ref-34146428','lexi-content-ref-34713692','lexi-content-ref-32943113','lexi-content-ref-30669921','lexi-content-ref-36601749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31794437','lexi-content-ref-34146428','lexi-content-ref-34713692','lexi-content-ref-32943113','lexi-content-ref-30669921','lexi-content-ref-36601749'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; indirect, via metabolite 9-carboxymethoxymethylguanine (CMMG) accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16540518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16540518'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; typically reported within 3 days of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34146428']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34146428'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Less established than with acyclovir, but may include:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19187258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19187258'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19187258','lexi-content-ref-16540518','lexi-content-ref-28765478','lexi-content-ref-14632595','lexi-content-ref-14692893','lexi-content-ref-36203771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19187258','lexi-content-ref-16540518','lexi-content-ref-28765478','lexi-content-ref-14632595','lexi-content-ref-14692893','lexi-content-ref-36203771'])">Ref</a></span>); however, some cases have been reported in normal kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29877263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29877263'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Advanced age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19187258','lexi-content-ref-29877263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19187258','lexi-content-ref-29877263'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thrombotic microangiopathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thrombotic thrombocytopenic purpura</b> (TTP) and <b>hemolytic-uremic syndrome</b> (HUS), manifestations of thrombotic microangiopathy, have been reported with both acyclovir and valacyclovir (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9352739','lexi-content-ref-32550073','lexi-content-ref-28356666','lexi-content-ref-10847274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9352739','lexi-content-ref-32550073','lexi-content-ref-28356666','lexi-content-ref-10847274'])">Ref</a></span>). TTP/HUS may result in damage to the brain, heart, kidney, liver, and pancreas (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12192020','lexi-content-ref-24237985']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12192020','lexi-content-ref-24237985'])">Ref</a></span>). Resolution has been reported with drug discontinuation and appropriate therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32550073','lexi-content-ref-28356666','lexi-content-ref-10847274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32550073','lexi-content-ref-28356666','lexi-content-ref-10847274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Idiosyncratic; thrombotic microangiopathy (and resulting TTP and HUS) involves endothelial cell injury, intravascular platelet-fibrin thrombi, and vascular damage (Trachtman 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; has been reported within 3 days of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28356666']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28356666'])">Ref</a></span>) and after 1 year of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32550073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32550073'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (largely unknown):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic susceptibility may play a role for drug-induced HUS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24237985']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24237985'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F232766"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (3% to 11%), nausea (8% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (HIV-1-infected patients: 18%)<span class="lexi-table-link-container"> (<a aria-label="Neutropenia table link" class="lexi-table-link" data-table-id="lexi-content-neutropenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-neutropenia')">table 1</a>)</span><span class="table-link" style="display:none;">Neutropenia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Neutropenia" frame="border" id="lexi-content-neutropenia" rules="all">
<caption style="text-align:center;">
<b>Valacyclovir: Adverse Reaction: Neutropenia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Valacyclovir</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (</b>
<b>Valacyclovir</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">500 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Suppression of recurrent genital herpes in HIV-1−infected subjects</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">194</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">99</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (2%; HIV-1-infected patients: 14%), increased serum aspartate aminotransferase (≤4%; HIV-1-infected patients: 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (13% to 38%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (HIV-1-infected patients: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (infants and children: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (infants and children: 5%; adults: &lt;1%), vomiting (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (5% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia (≤1%), thrombocytopenia (HIV-1-infected patients: 3%)<span class="lexi-table-link-container"> (<a aria-label="Thrombocytopenia table link" class="lexi-table-link" data-table-id="lexi-content-thrombocytopenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-thrombocytopenia')">table 2</a>)</span><span class="table-link" style="display:none;">Thrombocytopenia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Thrombocytopenia" frame="border" id="lexi-content-thrombocytopenia" rules="all">
<caption style="text-align:center;">
<b>Valacyclovir: Adverse Reaction: Thrombocytopenia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Valacyclovir)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (</b>
<b>Valacyclovir</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">500 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Suppression of recurrent genital herpes in HIV-1−infected subjects</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">194</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">99</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (HIV-1-infected patients: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (infants and children: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (7%), dizziness (2% to 4%), fatigue (HIV-1-infected patients: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (5% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinorrhea (infants and children: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (infants and children: 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, erythema multiforme, skin photosensitivity, urticaria (Singh 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary urgency</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, hemolytic-uremic syndrome (Bell 1997), thrombotic thrombocytopenic purpura (Bukhari 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (Renkes 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Ebo 2008), drug reaction with eosinophilia and systemic symptoms (Ingen-Housz-Oro 2019), hypersensitivity angiitis, hypersensitivity reaction (acute) (Lammintausta 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, agitation (Rivkin 2003), ataxia (Helldén 2006), coma (Carlon 2005), confusion (Yoshimura 2018), delirium (Asahi 2009), delusion (Helldén 2006), dysarthria (Asahi 2009), emotional lability (Memon 2021), encephalopathy (Guramrinder 2017), hallucination (Helldén 2006; Strumia 2004), loss of consciousness (Carlon 2005), mania, myoclonus (Strumia 2004), neuritis (Pary 2004), psychosis, seizure (Hoskote 2016), tremor (Prasad 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Kitano 2015; Sugimoto 2008)</p></div>
<div class="block coi drugH1Div" id="F232781"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to valacyclovir, acyclovir, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F232763"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution in patients with renal impairment; dosage adjustments may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For genital herpes, treatment should begin as soon as possible after the first signs and symptoms (within 72 hours of onset of first diagnosis or within 24 hours of onset of recurrent episodes).</p></div>
<div class="block foc drugH1Div" id="F232774"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valtrex: 500 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valtrex: 1 g [scored; contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg, 1 g</p></div>
<div class="block geq drugH1Div" id="F232759"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F232783"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (valACYclovir HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $11.62 - $12.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $3.97 - $7.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Valtrex Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $25.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $16.11</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868551"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valtrex: 500 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valtrex: 1 g [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg, 1000 mg, 1 g</p></div>
<div class="block exp drugH1Div" id="F6825106"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>50 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>
<p style="text-indent:-2em;margin-left:2em;">A 50 mg/mL oral suspension may be made with tablets, Ora-Plus, and either Ora-Sweet or Ora-Sweet SF. Crush eighteen 500 mg tablets in a mortar and reduce to a fine powder. Add 5 mL portions of Ora-Plus (40 mL total) and mix to a uniform paste; transfer to a 180 mL calibrated amber glass bottle, rinse mortar with 10 mL of Ora-Plus 5 times, then add quantity of syrup (Ora-Sweet or Ora-Sweet SF) sufficient to make 180 mL. Label "shake well" and "refrigerate." Stable for 21 days refrigerated.</p>
<div class="reference">Fish DN, Vidaurri VA, and Deeter RG, "Stability of Valacyclovir Hydrochloride in Extemporaneously Prepared Oral Liquids," <i>Am J Health Syst Pharm</i>, 1999, 56(19):1957-60.<span class="pubmed-id">10554914</span></div>
</div>
<div class="block admp drugH1Div" id="F52613993"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer with or without food; maintain adequate hydration.</p></div>
<div class="block adm drugH1Div" id="F232778"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">May administer with or without food; maintain adequate hydration.</p></div>
<div class="block sts drugH1Div" id="F232795"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 15°C to 25°C (59°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53569398"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of chickenpox in immunocompetent patients (FDA approved in ages 2 to &lt;18 years); treatment of herpes labialis (cold sores) (FDA approved in ages ≥12 years and adults); treatment of herpes zoster (shingles) in immunocompetent patients (FDA approved in adults); treatment of initial and recurrent episodes of genital herpes (FDA approved in adults); suppression of recurrent genital herpes and reduction of transmission of genital herpes in immunocompetent patients (FDA approved in adults); has also been used for prophylaxis of herpes simplex virus and varicella zoster virus in immunocompromised populations.</p></div>
<div class="block mst drugH1Div" id="F232826"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valtrex may be confused with Keflex, Valcyte, Zovirax</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ValACYclovir may be confused with acyclovir, valGANciclovir, vancomycin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300201"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3, OCT1; <b>Inhibits</b> CYP1A2 (weak)</p></div>
<div class="block dri drugH1Div" id="F232768"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foscarnet: May enhance the nephrotoxic effect of Acyclovir-Valacyclovir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Acyclovir-Valacyclovir may increase the serum concentration of Mycophenolate. Mycophenolate may increase the serum concentration of Acyclovir-Valacyclovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Antiherpetic Antivirals may diminish the therapeutic effect of Talimogene Laherparepvec. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Products: Acyclovir-Valacyclovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Acyclovir-Valacyclovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Varicella Virus Vaccine: Acyclovir-Valacyclovir may diminish the therapeutic effect of Varicella Virus Vaccine.  Management: When possible, avoid use of acyclovir or valacyclovir within the 24 hours prior to administration of the varicella vaccine, and avoid use of these antiviral agents for 14 days after vaccination.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zoster Vaccine (Live/Attenuated): Acyclovir-Valacyclovir may diminish the therapeutic effect of Zoster Vaccine (Live/Attenuated). <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F232784"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Following maternal administration of valacyclovir, acyclovir is detectable in the cord blood and amniotic fluid (Jacquemard 2007; Kimberlin 1998).</p>
<p style="text-indent:0em;margin-top:2em;">The valacyclovir pregnancy registry included information from 28 pregnancies with first-trimester valacyclovir exposure. Data from the registry, which closed in 1999, did not find a statistically significant increase in the number of birth defects with exposure to valacyclovir; however, data were limited and there were insufficient data regarding miscarriage or adverse maternal or fetal outcomes. Valacyclovir is metabolized to acyclovir; data from the acyclovir pregnancy registry did not find an increase in the number of birth defects with exposure to acyclovir when compared to those expected in the general population (refer to the Acyclovir monograph for additional information). A population-based registry study conducted in Denmark had similar results. The study used data from 1996 to 2008 and included 229 pregnancies with first-trimester valacyclovir exposure; an increased risk of birth defects was not observed (Pasternak 2010). One study observed an increased risk of gastroschisis following use of antiherpetic medications such as valacyclovir during the first trimester to treat maternal genital herpes; this risk was also increased in the offspring of women with genital herpes not receiving treatment (Ahrens 2013).</p>
<p style="text-indent:0em;margin-top:2em;">In a pharmacokinetic study, maternal acyclovir serum concentrations were higher in pregnant patients receiving valacyclovir than those given acyclovir for the suppression of recurrent herpes simplex virus (HSV) infection late in pregnancy. Amniotic fluid concentrations were also higher; however, there was no evidence that fetal exposure differed between the groups (Kimberlin 1998).</p>
<p style="text-indent:0em;margin-top:2em;">Valacyclovir is recommended for the treatment of genital HSV in pregnant patients. Primary HSV infection during the first trimester may be associated with neonatal chorioretinitis, microcephaly, and skin lesions. The risk of perinatal transmission is greater when the primary infection occurs during pregnancy. Maternal treatment decreases duration and severity of disease and duration of viral shedding (ACOG 2020). Suppressive therapy is recommended for patients beginning at 36 weeks' gestation who have a history of genital lesions (ACOG 2020; CDC [Workowski 2021]; HHS [OI adult] 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Valacyclovir has been studied for the treatment of congenital cytomegalovirus infection during pregnancy. Until additional data are available, use outside of a clinical trial is not currently recommended (Shahar-Nissan 2020; SMFM 2016; Zammarchi 2020).</p></div>
<div class="block mopp drugH1Div" id="F53569397"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Urinalysis, BUN, serum creatinine, liver enzymes, CBC.</p></div>
<div class="block pha drugH1Div" id="F232762"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Valacyclovir is rapidly and nearly completely converted to acyclovir by intestinal and hepatic metabolism. Acyclovir is converted to acyclovir monophosphate by virus-specific thymidine kinase then further converted to acyclovir triphosphate by other cellular enzymes. Acyclovir triphosphate inhibits DNA synthesis and viral replication by competing with deoxyguanosine triphosphate for viral DNA polymerase and being incorporated into viral DNA.</p></div>
<div class="block phk drugH1Div" id="F232780"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Acyclovir is widely distributed throughout the body including brain, kidney, lungs, liver, spleen, muscle, uterus, vagina, and CSF.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>: Acyclovir: Children ≥3 years and Adolescents: Mean: 1.34 ± 0.65 L/kg (Bomgaars 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Valacyclovir: 13.5% to 17.9%; Acyclovir: 9% to 33%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; valacyclovir is rapidly and nearly completely converted to acyclovir and L-valine by first-pass effect; acyclovir is hepatically metabolized to a very small extent by aldehyde oxidase and by alcohol and aldehyde dehydrogenase (inactive metabolites).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Acyclovir:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Tablet, extemporaneously prepared oral suspension: Mean range: 44% to 64%; varies based on formulation and age from 27.7% to 87% (Bomgaars 2008; Eksborg 2002; Kimberlin 2010; Nadal 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults (healthy volunteers): Tablet: 54.5% ± 9.1%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Acyclovir:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 1 to &lt;3 months: 2 hours (Kimberlin 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 3 to &lt;6 months: 1.8 hours (Kimberlin 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months: 1.3 hours (Kimberlin 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Mean range: 1.3 to 2.51 hours (Bomgaars 2008; Eksborg 2002; Kimberlin 2010; Nadal 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Normal renal function: 2.5 to 3.3 hours, Valacyclovir: ~30 minutes; End-stage renal disease: 14 to 20 hours; During hemodialysis: 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Acyclovir:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: Mean range: 1.41 to 2.62 hours (Bomgaars 2008; Eksborg 2002; Nadal 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 1.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine, primarily as acyclovir (89%); <b>Note:</b> Following oral administration of radiolabeled valacyclovir, 46% of the label is eliminated in the feces (corresponding to nonabsorbed drug), while 47% of the radiolabel is eliminated in the urine.</p></div>
<div class="block phksp drugH1Div" id="F51204418"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: C<sub>max</sub> (Acyclovir): Oral valacyclovir suspension (extemporaneously compounded): Single dose, 20 mg/kg (manufacturer's labeling):</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;2 years: 4.03 ± 1.37 mg/L.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;6 years: 3.75 ± 1.14 mg/L.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to &lt;12 years: 4.71 ± 1.2 mg/L.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F232787"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Valabin | Valtrex | Virico</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Rapivir | Valtrex | Viramixal | Viranet</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Valaciclovir actavis | Valaciclovir Arcana | Valaciclovir bluefish | Valaciclovir pfizer | Valaciclovir Stada | Valtrex | Viropel</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo valaciclovir | Apx valaciclovir | Chemmart valaciclovir | Noumed valaciclovir | Shilova | Terry white chemist valaciclovir | Vaclovir | Valaciclovir | Valaciclovir actavis | Valaciclovir an | Valaciclovir ga | Valaciclovir generic health | Valaciclovir rbx | Valaciclovir sandoz | Valaciclovir sz | Valacor | Valnir | Valtrex | Valvala | Zelitrex</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alaclov | Revira | Valarux | Valovir | Zostiva</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Valaciclovir Apotex | Valaciclovir mylan | Valaciclovir sandoz | Zelitrex</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Zelitrex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Valtrex</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de valaciclovir | Dazek | Herpstal | Valtrex</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Valaciclovir actavis | Valaciclovir Helvepharm | Valaciclovir Mepha | Valaciclovir sandoz | Valaciclovir Spirig | Valaciclovir Streuli | Valaciclovir teva | Valaciclovir therica | Valaciclovir zentiva | Valacivir mepha | Valtrex</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Alyvir | Zelitrex</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Pervioral | Vacper | Vadiral | Valtrex | Virmax</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A mai xin | Li ke fen | Li zhu wei | Ming zhu xin | Valacyclovir hydrochloride | Valtrex</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Clovirax | Hetval | Vadiral | Valaciclovir | Valclomed | Valclovir | Valcyclor | Valtrex | Valtrois | Valyc | Virentel</span>;</li>
<li>
<span class="countryCode">(CR)</span> <span class="country">Costa Rica</span><span class="countrySeparator">: </span><span class="drugName">Valvirex</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Valaciclovir +pharma | Valaciclovir mylan | Valtrex</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Valaciclovir 1 a pharma | Valaciclovir AL | Valaciclovir amneal | Valaciclovir aurobindo | Valaciclovir bluefish | Valaciclovir Hexal | Valaciclovir Orifam | Valtrex | Valtrex s</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Vadiral | Valtrex</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Pervioral | Vadiral | Valaciclovir | Valaciclovir mk | Valtrex</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Valaciclovir actavis | Valaciclovir Portfarma | Valtrex</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cicloherp | Herpacut | Valtrex | Valtrovir | Valysernex | Viroclear</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Tridiavir | Valaciclovir almus | Valaciclovir amneal | Valaciclovir arrow | Valaciclovir aurobindo | Valaciclovir Combix | Valaciclovir Kern | Valaciclovir Pharmacia | Valaciclovir Stada | Valaciclovir stada genericos | Valaciclovir tecnigen | Valaciclovir teva | Valherpes | Valpridol | Valtrex | Virval</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Flushnil | Valaciclovir actavis | Valaciclovir bluefish | Valaciclovir mylan | Valaciclovir orifarm | Valaciclovir pfizer | Valaciclovir Ratiopharm | Valaciclovir sandoz | Valaciclovir teva | Valavir | Valtrex | Zelitrex</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Valaciclovir actavis | Valaciclovir almus | Valaciclovir Alter | Valaciclovir Arrow generiques | Valaciclovir biogaran | Valaciclovir bluefish | Valaciclovir Bouchara Recordati | Valaciclovir Cristers | Valaciclovir EG | Valaciclovir evolugen | Valaciclovir isomed | Valaciclovir Mylan pharma | Valaciclovir pfizer | Valaciclovir phr | Valaciclovir Qualimed | Valaciclovir Ranbaxy | Valaciclovir Ratiopharm | Valaciclovir sandoz | Valaciclovir teva | Valaciclovir Teva pharma | Valaciclovir Winthrop | Valaciclovir zentiva | Valaciclovir Zydus France | Zelitrex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Valaciclovir | Valtrex</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Solvaprent | Valaciclovir/actavis | Valomed | Valtrex | Vociflon</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo valacyclovir | Valaciclovir actavis | Valaciclovir sandoz | Valtra | Valtrex</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Rivacir | Valtrex</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cloviar | Herclov | Iclofar | Inclovir | Valaciclovir | Valciron | Valtrex | Valvir | Vandavir | Zostavir</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Myval | Valaciclovir | Valaciclovir actavis | Valaciclovir bluefish | Valaciclovir teva | Valherp | Valotix | Valtrex</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Valtrex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Herpival | Valamac | Valanext | Valanix | Valcet | Valcivir | Valtoval | Zimivir</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Valablis</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Crevir | Talavir | Valaciclovir aurobindo | Valaciclovir EG | Valaciclovir generics mylan | Valaciclovir San | Valaciclovir tecnigen | Zelitrex</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Valtrex</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Valaciclovir | Valaciclovir aspen | Valaciclovir dk | Valaciclovir ffp | Valaciclovir meek | Valaciclovir sanwa | Valtrex</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Valovir | Valtrex | Viraval</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Balrasi | Herpozi | Newvalaclov | Pms valacyclovir | Vaciclovir | Valacil | Valaclor | Valarex | Valaxy | Valcicol | Valcivir | Valclex | Valclovior | Valclovir | Valex | Valraci | Valtavics | Valtcro | Valtllis | Valtmax | Valtra | Valtran | Valtrex | Valtris | Valtvala | Valvirus</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Valtrex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Valaciclovir arrow | Valcyk | Valtrex</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Valaciclovir 1 a pharma | Valaciclovir actavis | Valaciclovir actiofarma | Valaciclovir bluefish | Valaciclovir Hexal | Valaciclovir Portfarma | Valaciclovir puren | Valaciclovir teva | Valtrex</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Zelitrex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Valaciclovir actavis | Valaciclovir Combix | Valaciclovir Portfarma | Valtrex</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Alyvir | Valex | Zelitrex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Asfina | Rapivir | Valaciclovir | Valextra | Valinir | Vijay | Zelitrex | Zoclorida</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Axcel Valacyclovir | Valovir | Valtrex | Valvir</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Valtrex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Valaciclovir | Valaciclovir actavis | Valaciclovir aurobindo | Valaciclovir bluefish | Valaciclovir focus | Valaciclovir mylan | Valaciclovir PCH | Valaciclovir sandoz | Valtrex | Zelitrex</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Valaciclovir actavis | Valaciclovir bluefish | Valaciclovir orifarm | Valaciclovir sandoz | Valtrex</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Vaclovir</span>;</li>
<li>
<span class="countryCode">(PA)</span> <span class="country">Panama</span><span class="countrySeparator">: </span><span class="drugName">Valvicic</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Alyvir | Bagovir | Cephaming | Vadiral | Valtero | Valtrex | Valyc</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Valtrex</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Nexvalor | Vaclovir | Valahep | Valavir | Valtrex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Vaciclor | Valtrex</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Valacyclovir | Valacyclovir hcl | Valacyclovir hydrochloride | Valtrex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Azel | Crotax | Valaciclovir actavis | Valaciclovir amex | Valaciclovir aurobindo | Valaciclovir azevedos | Valaciclovir ciclum | Valaciclovir daquimed | Valaciclovir labesfal | Valavir | Valtrex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Clotie | Vadiral | Valtrex</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Valtrex</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Valtrex</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Vacirex | Valaciclovir | Valaciclovir canon | Valaciclovir obl | Valacitek | Valacyclovir | Valacyclovir velpharm | Valavir | Valcycon | Valmik | Valtrex | Valvir | Vayrova | Virdel</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo valacyclovir | Herptrex | Pms valacyclovir | Valtrex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Valaciclovir | Valaciclovir abacus medicine | Valaciclovir actavis | Valaciclovir alternova | Valaciclovir amneal | Valaciclovir arrow | Valaciclovir bluefish | Valaciclovir CC pharma | Valaciclovir mylan | Valaciclovir orifarm | Valaciclovir orion | Valaciclovir sandoz | Valaciclovir teva | Valaciklovir Ebb | Valtrex | Zeltrex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Vaciclor | Valovir | Valtrex</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Valaciklovir | Valaciklovir Teva | Valdacir | Valtrex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Valtrex</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Valtrex</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Aviral | Cyvaltex | Valcyvir | Zelitrex | Zelivir</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Valtrex | Vaxvire | Viromed</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Vacyless | Valacyclovir mylan | Valtrex | Vibox</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Herpeval | Valacyclovir hetero | Valavir | Valtrex</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Valovir</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Kalfed | Rapivir | Valaciclovir</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Vadiral | Valaciclovir | Valtrex</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Actiprez | Anviro | Hevitrex | Mylan valaciclovir | Shilova | Valatrex | Vavirex | Vorior | Zelitrex | Zelivire</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Alyvir</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Vaclovir | Valovir | Zelitrex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-35509998">
<a name="35509998"></a>Abuhelwa Z, Beran A, Venkataramany BS, Hinch BT, Assaly R. Concurrent nephrotoxicity and neurotoxicity induced by oral valacyclovir in a patient with previously normal kidney function. <i>Cureus</i>. 2022;14(3):e23693. doi:10.7759/cureus.23693<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/35509998/pubmed" id="35509998" target="_blank">35509998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23772935">
<a name="23772935"></a>Ahrens KA, Anderka MT, Feldkamp ML, Canfield MA, Mitchell AA, Werler MM; National Birth Defects Prevention Study. Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997-2007. <i>Paediatr Perinat Epidemiol</i>. 2013;27(4):340-345. doi:10.1111/ppe.12064<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/23772935/pubmed" id="23772935" target="_blank">23772935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17123607">
<a name="17123607"></a>Aizman A, Johnson MW, Elner SG. Treatment of acute retinal necrosis syndrome with oral antiviral medications. <i>Ophthalmology</i>. 2007;114(2):307-312.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/17123607/pubmed" id="17123607" target="_blank">17123607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Albrecht.1">
<a name="Albrecht.1"></a>Albrecht MA. Treatment of varicella (chickenpox) infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32332414">
<a name="32332414"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 220: Management of genital herpes in pregnancy. <i>Obstet Gynecol</i>. 2020;135(5):e193-e202. doi:10.1097/AOG.0000000000003840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/32332414/pubmed" id="32332414" target="_blank">32332414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelsons.1">
<a name="Nelsons.1"></a>Antimicrobial therapy according to clinical syndromes. In: Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 27th ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19187258">
<a name="19187258"></a>Asahi T, Tsutsui M, Wakasugi M, et al. Valacyclovir neurotoxicity: clinical experience and review of the literature. <i>Eur J Neurol</i>. 2009;16(4):457-460. doi:10.1111/j.1468-1331.2008.02527.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/19187258/pubmed" id="19187258" target="_blank">19187258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12055471">
<a name="12055471"></a>Aslanides IM, De Souza S, Wong DT, et al. Oral valacyclovir in the treatment of acute retinal necrosis syndrome. <i>Retina</i>. 2002;22(3):352-354.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/12055471/pubmed" id="12055471" target="_blank">12055471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12656408">
<a name="12656408"></a>Axelsson S, Lindberg S, Stjernquist-Desatnik A. Outcome of treatment with valacyclovir and prednisone in patients with Bell's palsy. <i>Ann Otol Rhinol Laryngol.</i> 2003;112(3):197-201. doi:10.1177/000348940311200301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/12656408/pubmed" id="12656408" target="_blank">12656408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12661753">
<a name="12661753"></a>Baker D, Eisen D. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. <i>Cutis.</i> 2003;71(3):239-242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/12661753/pubmed" id="12661753" target="_blank">12661753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17369082">
<a name="17369082"></a>Balfour HH Jr, Hokanson KM, Schacherer RM, et al. A Virologic Pilot Study of Valacyclovir in Infectious Mononucleosis. <i>J Clin Virol</i>. 2007;39(1):16-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/17369082/pubmed" id="17369082" target="_blank">17369082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24189771">
<a name="24189771"></a>Baugh RF, Basura GJ, Ishii LE, et al; American Academy of Otolaryngology—Head and Neck Surgery Foundation (AAO-HNSF). Clinical practice guideline: Bell's palsy. <i>Otolaryngol Head Neck Surg.</i> 2013;149(3)(suppl):S1-S27. doi:10.1177/0194599813505967<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/24189771/pubmed" id="24189771" target="_blank">24189771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9352739">
<a name="9352739"></a>Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). <i>Medicine (Baltimore)</i>. 1997;76(5):369-380. doi:10.1097/00005792-199709000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/9352739/pubmed" id="9352739" target="_blank">9352739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31794437">
<a name="31794437"></a>Bełz A, Dębowska P, Głogowska-Szeląg J. Acyclovir neurotoxicity in an elderly patient with end-stage renal failure. <i>Am J Ther</i>. 2020;27(5):e525-e527. doi:10.1097/MJT.0000000000001012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/31794437/pubmed" id="31794437" target="_blank">31794437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7492102">
<a name="7492102"></a>Beutner KR, Friedman DJ, Forszpaniak C, et al. Valacyclovir Compared With Acyclovir for Improved Therapy for Herpes Zoster in Immunocompetent Adults. <i>Antimicrob Agents Chemother</i>. 1995;39(7):1546-1553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/7492102/pubmed" id="7492102" target="_blank">7492102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18561175">
<a name="18561175"></a>Bomgaars L, Thompson P, Berg S, et al. Valacyclovir and Acyclovir Pharmacokinetics in Immunocompromised Children. <i>Pediatr Blood Cancer</i>. 2008;51(4):504-508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/18561175/pubmed" id="18561175" target="_blank">18561175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34146428">
<a name="34146428"></a>Brandariz-Nuñez D, Correas-Sanahuja M, Maya-Gallego S, Martín Herranz I. Neurotoxicity associated with acyclovir and valacyclovir: a systematic review of cases. <i>J Clin Pharm Ther</i>. 2021;46(4):918-926. doi:10.1111/jcpt.13464<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/34146428/pubmed" id="34146428" target="_blank">34146428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32550073">
<a name="32550073"></a>Bukhari S, Aslam HM, Awwal TA, Christmas D, Wallach SL. Valacyclovir-induced thrombotic thrombocytopenic purpura. <i>Cureus</i>. 2020;12(5):e8156. doi:10.7759/cureus.8156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/32550073/pubmed" id="32550073" target="_blank">32550073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16172845">
<a name="16172845"></a>Carlon R, Possamai C, Corbanese U. Acute renal failure and severe neurotoxicity following valacyclovir. <i>Intensive Care Med</i>. 2005;31(11):1593. doi:10.1007/s00134-005-2808-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/16172845/pubmed" id="16172845" target="_blank">16172845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12626280">
<a name="12626280"></a>Chauvin PJ, Ajar AH. Acute herpetic gingivostomatitis in adults: a review of 13 cases, including diagnosis and management. <i>J Can Dent Assoc</i>. 2002;68(4):247-251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/12626280/pubmed" id="12626280" target="_blank">12626280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10375341">
<a name="10375341"></a>Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. <i>Ann Intern Med.</i> 1999;130(11):922-932. doi:10.7326/0003-4819-130-11-199906010-00017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/10375341/pubmed" id="10375341" target="_blank">10375341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10919899">
<a name="10919899"></a>Colin J, Prisant O, Cochener B, Lescale O, Rolland B, Hoang-Xuan T. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. <i>Ophthalmology</i>. 2000;107(8):1507-1511.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/10919899/pubmed" id="10919899" target="_blank">10919899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30840531">
<a name="30840531"></a>D'Andrea MA, Spatz DL. Maintaining breastfeeding during severe infant and maternal HSV-1 infection: a case report. <i>J Hum Lact</i>. 2019;35(4):737-741. doi:10.1177/0890334419830994<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/30840531/pubmed" id="30840531" target="_blank">30840531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24934895">
<a name="24934895"></a>de Almeida JR, Guyatt GH, Sud S, et al; Bell Palsy Working Group, Canadian Society of Otolaryngology - Head and Neck Surgery and Canadian Neurological Sciences Federation. Management of Bell palsy: clinical practice guideline. <i>CMAJ</i>. 2014;186(12):917-922. doi:10.1503/cmaj.131801<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/24934895/pubmed" id="24934895" target="_blank">24934895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22509337">
<a name="22509337"></a>Drake AL, Roxby AC, Kiarie J, et al. Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial. <i>PLoS One</i>. 2012;7(4):e34635.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/22509337/pubmed" id="22509337" target="_blank">22509337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17143845">
<a name="17143845"></a>Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. <i>Clin Infect Dis</i>. 2007;44(suppl 1):S1-S26. doi:10.1086/510206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/17143845/pubmed" id="17143845" target="_blank">17143845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18588563">
<a name="18588563"></a>Ebo DG, Bridts CH, De Clerck LS, Stevens WJ. Immediate allergy from valacyclovir. <i>Allergy</i>. 2008;63(7):941-942. doi:10.1111/j.1398-9995.2008.01700.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/18588563/pubmed" id="18588563" target="_blank">18588563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12621507">
<a name="12621507"></a>Eisen D, Essell J, Broun ER, Sigmund D, DeVoe M. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. <i>Bone Marrow Transplant</i>. 2003;31(1):51-55. doi:10.1038/sj.bmt.1703817<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/12621507/pubmed" id="12621507" target="_blank">12621507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11920787">
<a name="11920787"></a>Eksborg S, Pal N, Kalin M, et al. Pharmacokinetics of Acyclovir in Immunocompromized Children With Leukopenia and Mucositis After Chemotherapy: Can Intravenous Acyclovir Be Substituted by Oral Valacyclovir? <i>Med Pediatr Oncole</i>. 2002;38(4):240-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/11920787/pubmed" id="11920787" target="_blank">11920787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18849193">
<a name="18849193"></a>Engström M, Berg T, Stjernquist-Desatnik A, et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet Neurol. </i>2008;7(11):993-1000. doi:10.1016/S1474-4422(08)70221-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/18849193/pubmed" id="18849193" target="_blank">18849193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17515400">
<a name="17515400"></a>Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. <i>Blood</i>. 2007;110(8):3071-3077.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/17515400/pubmed" id="17515400" target="_blank">17515400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9419169">
<a name="9419169"></a>Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. <i>J Infect Dis</i>. 1998;177(1):48-56. doi:10.1086/513804<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/9419169/pubmed" id="9419169" target="_blank">9419169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10554914">
<a name="10554914"></a>Fish DN, Vidaurri VA, Deeter RG. Stability of Valacyclovir Hydrochloride in Extemporaneously Prepared Oral Liquids. <i>Am J Health Syst Pharm</i>. 1999;56(19):1957-1960.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/10554914/pubmed" id="10554914" target="_blank">10554914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fishman.1">
<a name="Fishman.1"></a>Fishman JA, Alexander BD. Prophylaxis of infections in solid organ transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17668537">
<a name="17668537"></a>Gilbert SC. Suppressive therapy versus episodic therapy with oral valacyclovir for recurrent herpes labialis: efficacy and tolerability in an open-label, crossover study. <i>J Drugs Dermatol.</i> 2007;6(4):400-405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/17668537/pubmed" id="17668537" target="_blank">17668537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28356666">
<a name="28356666"></a>Goli R, Mukku KK, Devaraju SB, Uppin MS. Acyclovir-induced thrombotic microangiopathy. <i>Indian J Nephrol</i>. 2017;27(2):131-132. doi:10.4103/0971-4065.181453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/28356666/pubmed" id="28356666" target="_blank">28356666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23136264">
<a name="23136264"></a>Gronseth GS, Paduga R; American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2012;79(22):2209-2213. doi:10.1212/WNL.0b013e318275978c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/23136264/pubmed" id="23136264" target="_blank">23136264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22005269">
<a name="22005269"></a>Gunness P, Aleksa K, Bend J, Koren G. Acyclovir-induced nephrotoxicity: the role of the acyclovir aldehyde metabolite. <i>Transl Res</i>. 2011;158(5):290-301. doi:10.1016/j.trsl.2011.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/22005269/pubmed" id="22005269" target="_blank">22005269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18778190">
<a name="18778190"></a>Hato N, Sawai N, Teraoka M, et al. Valacyclovir for the treatment of Bell's palsy. <i>Expert Opin Pharmacother</i>. 2008;9(14):2531-2536. doi:10.1517/14656566.9.14.2531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/18778190/pubmed" id="18778190" target="_blank">18778190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16540518">
<a name="16540518"></a>Helldén A, Lycke J, Vander T, Svensson JO, Odar-Cederlöf I, Ståhle L. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment. <i>J Antimicrob Chemother</i>. 2006;57(5):945-949. doi:10.1093/jac/dkl067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/16540518/pubmed" id="16540518" target="_blank">16540518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24368610">
<a name="24368610"></a>Hoskote SS, Annapureddy N, Ramesh AK, Rose K, Jones JP. Valacyclovir and acyclovir neurotoxicity with status epilepticus. <i>Am J Ther</i>. 2016;23(1):e304-e306. doi:10.1097/MJT.0000000000000003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/24368610/pubmed" id="24368610" target="_blank">24368610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17577329">
<a name="17577329"></a>Hyland PL, Coulter WA, Abu-Ruman I, et al. Asymptomatic shedding of HSV-1 in patients undergoing oral surgical procedures and attending for noninvasive treatment. <i>Oral Dis.</i> 2007;13(4):414-418.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/17577329/pubmed" id="17577329" target="_blank">17577329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30222854">
<a name="30222854"></a>Ingen-Housz-Oro S, Bernier C, Gener G, et al. Valaciclovir: a culprit drug for drug reaction with eosinophilia and systemic symptoms not to be neglected. Three cases. <i>Br J Dermatol</i>. 2019;180(3):666-667. doi:10.1111/bjd.17207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/30222854/pubmed" id="30222854" target="_blank">30222854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17617198">
<a name="17617198"></a>Jacquemard F, Yamamoto M, Costa JM, et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. <i>BJOG</i>. 2007;114(9):1113-1121. doi:10.1111/j.1471-0528.2007.01308.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/17617198/pubmed" id="17617198" target="_blank">17617198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36399320">
<a name="36399320"></a>Kato K, Murakami R, Shiroto H, et al. Valacyclovir-associated acute kidney injury and encephalopathy in an elderly woman with normal kidney function: a case report. <i>CEN Case Rep</i>. 2023;12(2):221-225. doi:10.1007/s13730-022-00748-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/36399320/pubmed" id="36399320" target="_blank">36399320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26167456">
<a name="26167456"></a>Keller F, Schröppel B, Ludwig U. Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction. <i>World J Nephrol</i>. 2015;4(3):330-344. doi:10.5527/wjn.v4.i3.330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/26167456/pubmed" id="26167456" target="_blank">26167456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34032768">
<a name="34032768"></a>Kenzaka T, Sugimoto K, Goda K, Akita H. Acute kidney injury and acyclovir-associated encephalopathy after administration of valacyclovir in an elderly person with normal renal function: a case report and literature review. <i>Medicine (Baltimore)</i>. 2021;100(21):e26147. doi:10.1097/MD.0000000000026147<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/34032768/pubmed" id="34032768" target="_blank">34032768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9790357">
<a name="9790357"></a>Kimberlin DF, Weller S, Whitley RJ, et al. Pharmacokinetics of Oral Valacyclovir and Acyclovir in Late Pregnancy. <i>Am J Obstet Gynecol</i>. 1998;179(4):846-851.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/9790357/pubmed" id="9790357" target="_blank">9790357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20014952">
<a name="20014952"></a>Kimberlin DW, Jacobs RF, Weller S, et al. Pharmacokinetics and Safety of Extemporaneously Compounded Valacyclovir Oral Suspension in Pediatric Patients From 1 Month Through 11 years of Age. <i>Clin Infect Dis</i>. 2010;50(2):221-228.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/20014952/pubmed" id="20014952" target="_blank">20014952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35764333">
<a name="35764333"></a>Kirkland J, Suganthan P. Valacyclovir-associated acute kidney injury. <i>BMJ Case Rep</i>. 2022;15(6):e249552. doi:10.1136/bcr-2022-249552<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/35764333/pubmed" id="35764333" target="_blank">35764333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30222448">
<a name="30222448"></a>Kitano A, Motohashi H, Takayama A, Inui KI, Yano Y. Valacyclovir-induced acute kidney injury in Japanese patients based on the PMDA adverse drug reactions reporting database. <i>Ther Innov Regul Sci</i>. 2015;49(1):81-85. doi:10.1177/2168479014536897<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/30222448/pubmed" id="30222448" target="_blank">30222448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11553156">
<a name="11553156"></a>Lammintausta K, Mäkelä L, Kalimo K. Rapid systemic valaciclovir reaction subsequent to aciclovir contact allergy. <i>Contact Dermatitis</i>. 2001;45(3):181. doi:10.1034/j.1600-0536.2001.045003181.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/11553156/pubmed" id="11553156" target="_blank">11553156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30741619">
<a name="30741619"></a>Lee EJ, Jang HN, Cho HS, et al. The incidence, risk factors, and clinical outcomes of acute kidney injury (staged using the RIFLE classification) associated with intravenous acyclovir administration. <i>Ren Fail</i>. 2018;40(1):687-692. doi:10.1080/0886022X.2018.1487866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/30741619/pubmed" id="30741619" target="_blank">30741619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30859647">
<a name="30859647"></a>Lee DH, Zuckerman RA; AST Infectious Diseases Community of Practice. Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13526. doi:10.1111/ctr.13526<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/30859647/pubmed" id="30859647" target="_blank">30859647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33777579">
<a name="33777579"></a>Memon W, Rose EK, Akram A, Simba B. A unique case of valacyclovir toxicity and pseudobulbar affect in a patient on peritoneal dialysis. <i>Cureus</i>. 2021;13(2):e13494. doi:10.7759/cureus.13494<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/33777579/pubmed" id="33777579" target="_blank">33777579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21937692">
<a name="21937692"></a>Milano F, Pergam SA, Xie H, et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. <i>Blood</i>. 2011;118(20):5689-5696. doi:10.1182/blood-2011-06-361618<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/21937692/pubmed" id="21937692" target="_blank">21937692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12192020">
<a name="12192020"></a>Moake JL. Thrombotic microangiopathies. <i>N Engl J Med</i>. 2002;347(8):589-600. doi:10.1056/NEJMra020528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/12192020/pubmed" id="12192020" target="_blank">12192020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12353197">
<a name="12353197"></a>Nadal D, Leverger G, Sokal EM, et al. An Investigation of the Steady-State Pharmacokinetics of Oral Valacyclovir in Immunocompromised Children. <i>J Infect Dis</i>. 2002;186(suppl 1):S123-S130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/12353197/pubmed" id="12353197" target="_blank">12353197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34713692">
<a name="34713692"></a>Paluch Z, Trojánek M, Velíšková Z, et al. Neurotoxic side effects of acyclovir: two case reports. <i>Neuro Endocrinol Lett</i>. 2021;42(6):375-382.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/34713692/pubmed" id="34713692" target="_blank">34713692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15159513">
<a name="15159513"></a>Pary LF, Henszel A, Kelkar P. Vasculitic mononeuritis multiplex induced by valacyclovir. <i>Neurology</i>. 2004;62(10):1906-1907. doi:10.1212/01.wnl.0000125286.07723.8a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/15159513/pubmed" id="15159513" target="_blank">15159513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20736469">
<a name="20736469"></a>Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. <i>JAMA</i>. 2010;304(8):859-866. doi:10.1001/jama.2010.1206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/20736469/pubmed" id="20736469" target="_blank">20736469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10225250">
<a name="10225250"></a>Perazella MA. Crystal-induced acute renal failure. <i>Am J Med</i>. 1999;106(4):459-465. doi:10.1016/s0002-9343(99)00041-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/10225250/pubmed" id="10225250" target="_blank">10225250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31162727">
<a name="31162727"></a>Pergam SA, Limaye AP; AST Infectious Diseases Community of Practice. Varicella zoster virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13622. doi:10.1111/ctr.13622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/31162727/pubmed" id="31162727" target="_blank">31162727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29746903">
<a name="29746903"></a>Pott Junior H, de Oliveira MFB, Gambero S, Amazonas RB. Randomized clinical trial of famciclovir or acyclovir for the treatment of herpes zoster in adults. <i>Int J Infect Dis</i>. 2018;72:11-15. doi: 10.1016/j.ijid.2018.04.4324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/29746903/pubmed" id="29746903" target="_blank">29746903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28765478">
<a name="28765478"></a>Prasad B, McIsaac M, Toppings J. Valacyclovir-associated neurotoxicity treated with intensification of peritoneal dialysis. <i>BMJ Case Rep</i>. 2017;2017:bcr2017220678. doi:10.1136/bcr-2017-220678<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/28765478/pubmed" id="28765478" target="_blank">28765478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PHAC.1">
<a name="PHAC.1"></a>Public Health Agency of Canada. Canadian Guidelines on Sexually Transmitted Infections. <a href="http://www.phac-aspc.gc.ca/std-mts/sti-its/guide-lignesdir-eng.php" target="_blank">http://www.phac-aspc.gc.ca/std-mts/sti-its/guide-lignesdir-eng.php</a>. Accessed August 9, 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2080005">
<a name="2080005"></a>Rashed A, Azadeh B, Abu Romeh SH. Acyclovir-induced acute tubulo-interstitial nephritis. <i>Nephron</i>. 1990;56(4):436-438. doi:10.1159/000186190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/2080005/pubmed" id="2080005" target="_blank">2080005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10192972">
<a name="10192972"></a>Renkes P, Trechot P, Blain H. Valaciclovir-induced hepatitis. <i>Acta Clin Belg</i>. 1999;54(1):17-18. doi:10.1080/17843286.1999.11754203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/10192972/pubmed" id="10192972" target="_blank">10192972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30083888">
<a name="30083888"></a>Richelsen RKB, Jensen SB, Nielsen H. Incidence and predictors of intravenous acyclovir-induced nephrotoxicity. <i>Eur J Clin Microbiol Infect Dis</i>. 2018;37(10):1965-1971. doi:10.1007/s10096-018-3332-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/30083888/pubmed" id="30083888" target="_blank">30083888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Riley.1">
<a name="Riley.1"></a>Riley LE, Wald A. Genital herpes simplex virus infection and pregnancy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10847274">
<a name="10847274"></a>Rivaud E, Massiani MA, Vincent F, Azoulay E, Coudrec LJ. Valacyclovir hydrochloride therapy and thrombotic thrombocytopenic purpura in an HIV-infected patient. <i>Arch Intern Med</i>. 2000;160(11):1705-1706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/10847274/pubmed" id="10847274" target="_blank">10847274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14632595">
<a name="14632595"></a>Rivkin AM. Valacyclovir-induced seizures in end-stage renal disease. <i>Ann Pharmacother</i>. 2003;37(12):1913. doi:10.1345/aph.1D175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/14632595/pubmed" id="14632595" target="_blank">14632595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32943113">
<a name="32943113"></a>Robertson KM, Harvey CL, Cunningham JM. Acyclovir-induced neurotoxicity with a positive cerebrospinal fluid varicella zoster PCR result creating a management dilemma: a case report. <i>J Med Case Rep</i>. 2020;14(1):156. doi:10.1186/s13256-020-02498-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/32943113/pubmed" id="32943113" target="_blank">32943113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32404442">
<a name="32404442"></a>Sandery BJ, Erlich JH, Kennedy SE. Acute kidney injury following intravenous acyclovir in children. <i>Arch Dis Child</i>. 2020;105(12):1215-1219. doi:10.1136/archdischild-2019-317990<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/32404442/pubmed" id="32404442" target="_blank">32404442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34182607">
<a name="34182607"></a>Schurder J, Lazareth H, Mrad J, Thervet E, Benachi A, Vivanti AJ. Acute kidney injury after valacyclovir administration for prevention of congenital cytomegalovirus infection. <i>Ultrasound Obstet Gynecol</i>. 2021;58(4):636-637. doi:10.1002/uog.23724<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/34182607/pubmed" id="34182607" target="_blank">34182607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shaik.2019">
<a name="Shaik.2019"></a>Shaik A, Tandon V, Azmeen A. Nephrotoxicity associated with valacyclovir: when cold sores are sore to deal with. <i>CHEST</i>. 2019;156(4):A2050.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32919517">
<a name="32919517"></a>Shahar-Nissan K, Pardo J, Peled O, et al. Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2020;396(10253):779-785. doi:10.1016/S0140-6736(20)31868-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/32919517/pubmed" id="32919517" target="_blank">32919517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11810093">
<a name="11810093"></a>Sheffield JS, Fish DN, Hollier LM, Cadematori S, Nobles BJ, Wendel GD Jr. Acyclovir concentrations in human breast milk after valaciclovir administration. <i>Am J Obstet Gynecol</i>. 2002;186(1):100-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/11810093/pubmed" id="11810093" target="_blank">11810093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26515842">
<a name="26515842"></a>Singh SK, Prabhu A, Kumar A. Valacyclovir-induced urticaria without acyclovir hypersensitivity. <i>Indian J Dermatol Venereol Leprol</i>. 2015;81(6):611-612. doi:10.4103/0378-6323.168346<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/26515842/pubmed" id="26515842" target="_blank">26515842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26902990">
<a name="26902990"></a>Society for Maternal-Fetal Medicine (SMFM), Hughes BL, Gyamfi-Bannerman C. Diagnosis and antenatal management of congenital cytomegalovirus infection. <i>Am J Obstet Gynecol</i>. 2016;214(6):B5-B11. doi:10.1016/j.ajog.2016.02.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/26902990/pubmed" id="26902990" target="_blank">26902990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12021536">
<a name="12021536"></a>Stathoulopoulou F, Dhillon S, Thodis H, Stathakis C, Vargemezis V. Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients. <i>Nephron</i>. 2002;91(1):164-166. doi:10.1159/000057621<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/12021536/pubmed" id="12021536" target="_blank">12021536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14692893">
<a name="14692893"></a>Strumia S, De Mitri P, Bionda E. Neurotoxicity of acyclovir and valacyclovir in a hemodialyzed patient. <i>Eur J Neurol</i>. 2004;11(1):68-69. doi:10.1046/j.1351-5101.2003.00719.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/14692893/pubmed" id="14692893" target="_blank">14692893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18180255">
<a name="18180255"></a>Sugimoto T, Yasuda M, Sakaguchi M, et al. Oliguric acute renal failure following oral valacyclovir therapy. <i>QJM</i>. 2008;101(2):164-166. doi:10.1093/qjmed/hcm154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/18180255/pubmed" id="18180255" target="_blank">18180255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30179565">
<a name="30179565"></a>Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update [published online ahead of print September 4, 2018].<i> J Clin Oncol.</i> doi:10.1200/JCO.18.00374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/30179565/pubmed" id="30179565" target="_blank">30179565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35832570">
<a name="35832570"></a>Tarpey AE, Loranger A, Plambeck R, Malesker MA. Neurotoxicity secondary to valacyclovir. <i>J Pharm Technol</i>. 2022;38(4):251-252. doi:10.1177/87551225221098878<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/35832570/pubmed" id="35832570" target="_blank">35832570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28536235">
<a name="28536235"></a>Thind GS, Roach R. A case of acyclovir neurotoxicity presenting with atypical cerebrospinal fluid findings. <i>BMJ Case Rep</i>. 2017;2017:bcr2017220372. doi:10.1136/bcr-2017-220372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/28536235/pubmed" id="28536235" target="_blank">28536235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction appears in <i>Biol Blood Marrow Transplant</i>. 2010;16(2):294]. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24237985">
<a name="24237985"></a>Trachtman H. HUS and TTP in Children. <i>Pediatr Clin North Am</i>. 2013;60(6):1513-1526. doi:10.1016/j.pcl.2013.08.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/24237985/pubmed" id="24237985" target="_blank">24237985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18582201">
<a name="18582201"></a>Tunkel AR, Glaser CA, Bloch KC, et al; Infectious Diseases Society of America. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2008;47(3):303-327. doi:10.1086/589747<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/18582201/pubmed" id="18582201" target="_blank">18582201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30669921">
<a name="30669921"></a>Umoru GO, Shah PJ, Tariq F. A case report of neurotoxicity after prolonged doses of acyclovir in a patient with renal dysfunction. <i>J Pharm Pract</i>. 2020;33(2):217-221. doi:10.1177/0897190018825033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/30669921/pubmed" id="30669921" target="_blank">30669921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines</a>. Updated September 25, 2023. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>. Updated March 19, 2021. Accessed April 26, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Valtrex.1">
<a name="Valtrex.1"></a>Valtrex (valacyclovir) [prescribing information]. Durham, NC: GlaxoSmithKline; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36601749">
<a name="36601749"></a>Vonberg FW, Dawson A, Scott G, Davies N. Aciclovir-induced neurotoxicity. <i>Pract Neurol</i>. 2023;23(2):157-159. doi:10.1136/pn-2022-003597<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/36601749/pubmed" id="36601749" target="_blank">36601749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29877263">
<a name="29877263"></a>Yoshimura T, Kawasaki T, Shirota A, Saeki M, Okada Y, Okada H. Valacyclovir-induced neurotoxicity in a patient with a preserved renal function. <i>Intern Med</i>. 2018;57(21):3213-3216. doi:10.2169/internalmedicine.0403-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/29877263/pubmed" id="29877263" target="_blank">29877263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wald.1">
<a name="Wald.1"></a>Wald A, Johnston C. Treatment and prevention of herpes simplex virus type 1 in immunocompetent adolescents and adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36203771">
<a name="36203771"></a>Wang YC, Juan SH, Li CH, et al. Valacyclovir-associated neurotoxicity among patients on hemodialysis and peritoneal dialysis: a nationwide population-based study. <i>Front Med (Lausanne)</i>. 2022;9:997379. doi:10.3389/fmed.2022.997379<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/36203771/pubmed" id="36203771" target="_blank">36203771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wingard.1">
<a name="Wingard.1"></a>Wingard JR. Prevention of viral infections in hematopoietic cell transplant recipients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32289479">
<a name="32289479"></a>Zammarchi L, Lazzarotto T, Andreoni M, et al. Management of cytomegalovirus infection in pregnancy: is it time for valacyclovir? <i>Clin Microbiol Infect</i>. 2020;26(9):1151-1154. doi:10.1016/j.cmi.2020.04.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valacyclovir-pediatric-drug-information/abstract-text/32289479/pubmed" id="32289479" target="_blank">32289479</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13001 Version 474.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
